Aachen, Germany

Nikolay Sitnikov

This inventor holds 2 USPTO granted patents and 3 published patent applications and 1 EPO patent. Top assignee: Grunenthal Gmbh. Active years: 2020-2024.

USPTO Granted Patents = 2 

% Patents Active = 100.0

 

Average Co-Inventor Count = 6.4

ph-index = 1


Company Filing History:


Years Active: 2020-2024

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: Innovations of Nikolay Sitnikov

Introduction

Nikolay Sitnikov is a prominent inventor based in Aachen, Germany. He has made significant contributions to the field of medicine through his innovative patents. With a total of two patents to his name, Sitnikov's work focuses on developing compounds that address various medical conditions.

Latest Patents

One of Sitnikov's latest patents is for substituted pyrazole amides. This invention relates to compounds that act as inhibitors of Na1.8 and can be utilized in the treatment of pain. Another notable patent is for 1,3-diaza-spiro-[3.4]-octane derivatives. This invention encompasses the preparation and use of these derivatives in medicine, particularly for treating neurological disorders, including pain, neurodegenerative disorders, neuroinflammatory disorders, and neuropsychiatric disorders.

Career Highlights

Nikolay Sitnikov is currently employed at Grünenthal GmbH, a company known for its focus on pain management and innovative pharmaceutical solutions. His work at Grünenthal has allowed him to contribute to the development of new therapeutic options for patients.

Collaborations

Sitnikov has collaborated with notable colleagues, including Ingo Konetzki and Sebastian Krueger. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Nikolay Sitnikov's contributions to the field of medicine through his patents demonstrate his commitment to advancing healthcare solutions. His innovative work continues to impact the treatment of various medical conditions.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…